U.S. blank check firms eyeing cannabis companies are struggling to find suitable targets and many are merging into unrelated industries, as weak after market performance of recent Special Purpose Acquisition Corps listings dent confidence. Despite the challenges faced by SPACs and the public markets, private venture capital has remained strong, forcing SPACs to overpay when buying a private company, said Bill Growney, a Technology and Life Sciences partner at Goodwin. Read the Reuters article here.